Gynecology Collaboration and Licensing Agreement Trends Analysis Report 2025 | Access to 150 Deals Signed Since 2016 - Upfront, Milestone, Royalties by Company A-Z, Therapy Focus and Technology Type - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gynecology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.

Gynecology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gynecology deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 150 gynecology deals from 2016 to 2025. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gynecology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the gynecology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in gynecology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of gynecology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of gynecology deals listed by therapeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Gynecology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gynecology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Gynecology Collaboration and Licensing Deals includes:

• Trends in gynecology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of gynecology deal records covering pharmaceutical and biotechnology
• The leading gynecology deals by value
• Most active gynecology licensing dealmakers

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in gynecology dealmaking

2.1. Introduction

2.2. Gynecology partnering over the years

2.3. Gynecology partnering by deal type

2.4. Gynecology partnering by industry sector

2.5. Gynecology partnering by stage of development

2.6. Gynecology partnering by technology type

2.7. Gynecology partnering by therapeutic indication

Chapter 3 - Financial deal terms for gynecology partnering

3.1. Introduction

3.2. Disclosed financials terms for gynecology partnering

3.3. Gynecology partnering headline values

3.4. Gynecology deal upfront payments

3.5. Gynecology deal milestone payments

3.6. Gynecology royalty rates

Chapter 4 - Leading gynecology deals and dealmakers

4.1. Introduction

4.2. Most active in gynecology partnering

4.3. List of most active dealmakers in gynecology

4.4. Top gynecology deals by value

Chapter 5 - Gynecology contract document directory

5.1. Introduction

5.2. Gynecology partnering deals where contract document available

Chapter 6 - Gynecology dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by gynecology therapeutic target

Companies Featured

• 23andMe
• Aarhus University
• Abbott Laboratories
• Abbvie
• Accord Healthcare
• Acerus
• Ache
• AdaptivEndo
• Advaxis
• Adynxx
• AIMA Laboratories
• AIVF
• Allakos
• Allegheny Technologies
• Altavant Sciences
• Amag Pharmaceuticals
• American Dental Association
• Amring Pharmaceuticals
• AntibioTx
• ApolloBio
• Aptorum Group
• Ascend Therapeutics
• Asieris MediTech
• ASKA Pharmaceuticals
• Aspen Pharmacare Canada
• AstraZeneca
• Auransa
• Avion Pharmaceuticals
• Avomeen
• Bayer
• Besins Healthcare
• Bill and Melinda Gates Foundation
• Biofourmis
• BioGen Medical
• BioNano Genomics
• BioPep
• BioSyent Pharma
• BioVaxys
• Bloom Fertility
• BMV Medica
• Brigham and Women's Hospital
• California Cryobank
• Cancer Prevention and Research Institute of Texas
• Celmatix
• Chinese Academy of Sciences
• Chugai Pharmaceutical
• Cicero Diagnostics
• Co-Diagnostics
• Cocrystal Pharma
• Conceptions Reproductive Associates of Colorado
• Conduit Pharmaceuticals
• Consortia Health
• ConTipi
• Control Flo Medical
• Coriell Life Sciences
• Cosette Pharmaceuticals
• CR Pharma
• Dare Bioscience
• Department of Defense
• Dewpoint Therapeutics
• Duke University
• Easton Pharmaceuticals
• Egalet
• Embr Labs
• Emory University
• EndoCeutics
• Enzyvant Science
• Especificos Stendhal
• Eurofins LifeCodexx
• European Board and College of Obstetrics and Gynaecology
• European Wellness Biomedical Group
• Evidation Health
• Evofem Biosciences
• Evotec
• Evvy
• Exeltis
• Expedeon
• ExSeed
• Ferring Pharmaceuticals
• Flo Health
• Foresee Pharmaceuticals
• Fujifilm Irvine Scientific
• Fuji Pharma
• Gameto
• Gedeon Richter
• Genea Biomedx
• Genetiks
• Genome Medical
• Genomic Prediction
• German Cancer Research Center
• Gilead Sciences
• GOG Foundation
• Good Start Genetics
• Granata Bio
• Guided Therapeutics
• Gynica
• Halt Medical
• Hammock Pharmaceuticals
• Health Decisions
• Helix
• Helix BioPharma
• Highmark Health
• Hologic
• Hope Medicine
• Hyloris Pharmaceuticals
• IBSA Group
• iGenomix
• Igyxos
• Illumina
• Indegene Lifesystems
• InnerOptic Technology
• Innovative Health Diagnostics
• Inovio Pharmaceuticals
• Inserm Transfert
• INVO Bioscience
• Jiangsu Hansoh Pharmaceutical
• Jiangsu Hengrui Medicine
• Johns Hopkins University
• Joylux
• Karolinska Institute
• KinoPharma
• Knight Therapeutics
• LinKinVax
• LUCA Science
• Lumir Lab
• mAbXience
• Massachusetts General Hospital
• Mayne Pharma
• MD Anderson Cancer Center
• MDNA Life Sciences
• Medinova
• Meitheal Pharmaceuticals
• Menarini
• MenoGeniX
• Merck and Co
• Merck KGaA
• Microbix Biosystems
• MicroGenDX
• MilanaPharm
• Millendo Therapeutics
• Millicent Pharma
• Milu Labs
• Mithra Pharmaceuticals
• Morphic Therapeutic
• Mundipharma
• MyBiotics Pharma
• Mycovia Pharmaceuticals
• Myovant Sciences
• Nanjing King-friend Biochemical Pharmaceutical
• National Human Genome Research Institute
• National Institute of Child Health and Human Development
• National Institute on Aging
• National Institutes of Health
• Novan
• NuProbe
• NX Prenatal
• ObsEva
• OmniVision Technologies
• OncoNano Medicine
• One Drop
• Osel
• Osivax
• Osteolabs
• Ovation
• Oviva Therapeutics
• OvuSense
• Palatin Technologies
• PaxGenBio
• PDS Biotechnology
• Pearsanta
• Pfizer
• PharmaJet
• Pharmanest
• Phase Genomics
• Photocure ASA
• Pierre Fabre
• PolarisQB
• Predictive Technology Group
• Procare Health
• Psyche Systems
• Purna Pharmaceuticals
• QIAGEN
• Radius Health
• Rebiotix
• ReproCell
• Roivant Sciences
• Royal Philips Electronics
• Scholar Rock
• Searchlight Pharma
• Selexis
• Sema4
• Shandong Yaohua Medical Instrument
• Shenghuo Medical
• Skive Hospital
• Starpharma
• Statens Serum Institute
• St George Street Capital
• Strainprint Technologies
• Sumitomo Dainippon Pharma
• Sumitovant Biopharma
• Sun Pharmaceutical
• Syneos Health
• SynteractHCR
• Systems Oncology
• Takeda Pharmaceutical
• Tessa Therapeutics
• Texas A&M University
• Theramex
• TherapeuticsMD
• Thermo Fisher Scientific
• TiumBio
• TMRW Life Sciences
• Transgene
• twoXAR
• Ulisse Biomed
• University of Antwerp
• University of Illinois
• University of Leuven
• University of Oxford
• UpScriptHealth
• Urovant Sciences
• Vaccibody
• Valeo Pharma
• Veritas
• Viatris
• VICHY Laboratoires
• Viramal
• VirtaMed
• Vitro Biopharma
• Woom
• Xbrane Biopharma
• Xisle Pharma Ventures Trust

For more information about this report visit https://www.researchandmarkets.com/r/tlz9og

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.